A Member of the University of Maryland Medical System | In Partnership with the University of Maryland School of Medicine

Get answers to your child's growth, nutrition, and feeding behavior questions.
Growth and Nutrition Experts’s Bio | Q&A Archive
Sphingomyelinase deficiency
At this time, there is no effective treatment for Type A.
Bone marrow transplantation has been performed on a few patients with Type B with encouraging results. Researchers continue to study possible treatments, including enzyme replacement therapy and gene therapy.
There is no specific treatment for Type D. Recently a new treatment called miglustat has been approved for type C.
A healthy, low-cholesterol diet is recommended, although research into low-cholesterol diets and cholesterol-lowering drugs does not show that these methods stop the disease from getting worse or change how cells break down cholesterol. However, medicines are available to control or relieve many symptoms, such as cataplexy and seizures.
For more information, visit the National Niemann-Pick Disease Foundation website:
Type A Niemann-Pick is a severe disease, which generally leads to death by age 2 or 3.
Those with Type B may live into late childhood or adulthood.
A child who shows signs of Type C before age 1 may not live to school age. Those who show show symptoms after entering school may live into their mid-to-late teens, with a few surviving into the 20s.
Make an appointment with your health care provider if you have a family history of Niemann-Pick disease and you plan to have children. Genetic counseling and screening is recommended.
Call your health care provider if your child has symptoms of this disease, including
NP-C Guidelines Working Group, Wraith JE, Baumgartner MR, Bembi B, Covanis A, Levade T, Mengel E, et al. Recommendations on the diagnosis and management of Niemann-Pick disease type C. Mol Genet Metab. 2009;98:152-165.
Stanley CA, Bennett MJ. Defects of metabolism in lipids. In: Kliegman RM, Behrman RE, Jenson HB, Stanton BF, eds. Nelson Textbook of Pediatrics. 18th ed. Philadelphia, Pa: Saunders Elsevier; 2007:chap 86.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
© 2011 University of Maryland Medical Center (UMMC). All rights reserved.
UMMC is a member of the University of Maryland Medical System,
22 S. Greene Street, Baltimore, MD 21201. TDD: 1-800-735-2258 or 1.866.408.6885